Profile data is unavailable for this security.
About the company
Recce Pharmaceuticals Ltd is an Australia-based company. The Company is engaged in the development and commercialization of a new class of synthetic anti-infectives designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens. The Company's anti-infective pipeline includes three broad-spectrum, synthetic polymer anti-infectives: RECCE 327 as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria including their superbug forms; RECCE 435 as an orally administered therapy for bacterial infections; and RECCE 529 for viral infections. Through their multi-layered mechanisms of action, the Company's anti-infectives have the potential to overcome the processes utilized by bacteria and viruses to overcome resistance.
- Revenue in AUD (TTM)7.70m
- Net income in AUD-21.43m
- Incorporated2007
- Employees--
- LocationRecce Pharmaceuticals LtdLevel 23180 George St, Salesforce TowerSYDNEY 2000AustraliaAUS
- Phone+61 29000-1907
- Fax+61 28075-4584
- Websitehttps://www.recce.com.au/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Radiopharm Theranostics Ltd | 3.63m | -38.34m | 81.52m | 14.00 | -- | 1.21 | -- | 22.44 | -0.0179 | -0.0179 | 0.0017 | 0.0189 | 0.0458 | -- | 0.6382 | 259,530.70 | -48.38 | -- | -59.58 | -- | 1.08 | -- | -1,055.27 | -- | -- | -7.52 | 0.00 | -- | 1,114.26 | -- | 20.04 | -- | -- | -- |
| Biome Australia Ltd | 18.49m | 214.66k | 93.50m | 30.00 | 451.61 | 19.82 | 204.75 | 5.06 | 0.0009 | 0.0009 | 0.0833 | 0.0212 | 1.83 | 2.39 | 5.14 | -- | 2.12 | -43.09 | 5.42 | -74.65 | 61.27 | 60.84 | 1.16 | -31.29 | 1.02 | 1.80 | 0.3966 | -- | 41.43 | 80.32 | 112.85 | -- | 2.18 | -- |
| Botanix Pharmaceuticals Ltd | 5.76m | -86.40m | 124.21m | 1.00 | -- | 1.35 | -- | 21.58 | -0.0466 | -0.0466 | 0.0031 | 0.0415 | 0.0477 | 0.2477 | 3.48 | -- | -71.53 | -50.27 | -81.16 | -56.02 | 36.99 | -- | -1,500.65 | -1,888.17 | 2.87 | -- | 0.2226 | -- | 856.64 | 102.14 | -522.91 | -- | 63.43 | -- |
| Vita Life Sciences Ltd | 93.27m | 10.44m | 145.84m | 124.00 | 14.56 | 2.63 | -- | 1.56 | 0.1833 | 0.1833 | 1.64 | 1.01 | 1.21 | 2.29 | 7.28 | -- | 13.52 | 15.15 | 18.79 | 21.21 | 61.15 | 59.76 | 11.18 | 11.85 | 2.10 | -- | 0.0409 | 57.39 | 17.31 | 14.95 | 18.80 | 11.36 | 44.98 | 26.93 |
| Recce Pharmaceuticals Ltd | 7.70m | -21.43m | 156.16m | -- | -- | -- | -- | 20.27 | -0.0899 | -0.0899 | 0.0325 | -0.0106 | 0.8203 | -- | 25.91 | -- | -228.15 | -150.15 | -- | -318.01 | -- | -- | -278.12 | -340.57 | -- | -17.98 | 1.49 | -- | 47.14 | 46.35 | -21.33 | -- | 34.71 | -- |
| Starpharma Holdings Ltd | 13.86m | -3.23m | 193.16m | 50.00 | -- | 8.99 | -- | 13.94 | -0.0077 | -0.0077 | 0.0331 | 0.0512 | 0.4968 | 0.6233 | 3.55 | -- | -11.58 | -26.74 | -13.95 | -32.74 | 90.67 | 74.76 | -23.32 | -268.76 | 4.86 | -- | 0.0355 | -- | -49.65 | -5.61 | -22.35 | -- | -19.60 | -- |
| Mayne Pharma Group Ltd | 410.85m | -82.21m | 204.74m | 450.00 | -- | 0.5805 | -- | 0.4983 | -1.04 | -1.05 | 5.18 | 4.34 | 0.3967 | 2.80 | 2.35 | 913,002.30 | -7.94 | -15.32 | -10.90 | -20.87 | 62.98 | 53.04 | -20.01 | -64.51 | 1.14 | -11.97 | 0.1075 | -- | 4.44 | -2.04 | 46.58 | -- | -9.26 | -- |
| Holder | Shares | % Held |
|---|---|---|
| FIL Investment Management (Hong Kong) Ltd.as of 31 Dec 2025 | 15.99m | 5.53% |
| Macquarie Bank Ltd. (Private Banking)as of 17 Apr 2025 | 11.57m | 4.00% |
| FIL Pensions Managementas of 30 Jun 2025 | 5.31m | 1.84% |
| Pictet Asset Management SAas of 30 Jun 2025 | 43.45k | 0.02% |
| Pictet Asset Management (Singapore) Pte Ltd.as of 30 Jun 2025 | 0.00 | 0.00% |
